Get the Stockscreener App
90.85
0.75%
0.68
After Hours:
91.00
0.15
+0.17%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $90.85, with a volume of 6.84M.
It is up +0.75% in the last 24 hours and up +11.17% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$90.17
Open:
$90.69
24h Volume:
6.84M
Relative Volume:
1.36
Market Cap:
$281.69B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.17
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
-2.65%
1M Performance:
+11.17%
6M Performance:
+26.50%
1Y Performance:
+33.50%
1-Day Range:
$90.52
$91.28
1-Week Range:
$90.14
$92.98
52-Week Range:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
90.85 | 279.58B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Benzinga
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Benzinga
AstraZeneca's Hard To Control Hypertension Drug Advances, With FDA Decision Expected In 2026 - Benzinga
How AstraZeneca PLC (ZEG) stock correlates with oil marketsTrade Signal Summary & Daily Profit Focused Stock Screening - Newser
AstraZeneca (AZN) Named One of BofA's Top 25 Stocks for 2026 - Finviz
AstraZeneca stock price target raised to GBP155 by Morgan Stanley - Investing.com UK
AstraZeneca Remains Top Pick at Morgan StanleyBN - MarketScreener
AstraZeneca (AZN) Named One of BofA’s Top 25 Stocks for 2026 - Yahoo Finance
UK Government to Consult Executives from AstraZeneca, GSK on New Drug Pricing Regime - MarketScreener
COPD Market to Expand Significantly by 2034, States DelveInsight Report | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZeneca - Barchart.com
Pangaea and AstraZeneca forge multimodal AI partnership - Medical Device Network
AstraZeneca, GSK to Join UK Working Group on New Drug-Pricing Framework - MarketScreener
AstraZeneca (AZN) Gains FDA Priority Review for Hypertension Dru - GuruFocus
UK Government Partners with AstraZeneca (AZN) for Drug Pricing S - GuruFocus
FDA grants priority review for AstraZeneca’s hypertension drug baxdrostat By Investing.com - Investing.com UK
AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review - Citeline News & Insights
AstraZeneca's Potential First-in-class Hypertension Drug Moves Closer to US Approval - MarketScreener
AstraZeneca’s hypertension drug baxdrostat gets FDA priority review By Investing.com - Investing.com UK
How AstraZeneca PLC (Common Stock) (ZEGA) stock compares with top peersJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - Newser
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com South Africa
AstraZeneca issues 67,907 shares under employee share plans in latest period By Investing.com - Investing.com South Africa
AstraZeneca issues 67,907 shares under employee share plans in latest period - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca to invest $2B in Maryland manufacturing expansion - Manufacturing Dive
AstraZeneca Announces Updated Share Capital and Voting Rights - TipRanks
U.S.-U.K. Pharmaceutical Pricing Agreement to Benefit AstraZenec - GuruFocus
Faron appoints former AstraZeneca Netherlands finance chief as CFO - MarketScreener
UK Nears Pharmaceuticals Deal with US Benefiting AstraZeneca (AZ - GuruFocus
AstraZeneca Leads OMXS30 Gains in November - MarketScreener
How Recent Shifts Are Changing the Analyst Story for AstraZeneca - Yahoo Finance UK
What drives AstraZeneca PLC ZEG stock priceLow Beta Stocks & Discover Stocks Experts Are Watching - earlytimes.in
My time working with the manufacturer of the AstraZeneca drug substance - substack.com
AstraZeneca or Merck: Which Oncology Giant Has the Edge? - Yahoo Finance
AstraZeneca latest news: supports hold above GBX 13,200 as technicals remain strong - Traders Union
AstraZeneca Rises on 8 of Last 10 Days--Top Performer Among OMXS30 Stocks - MarketScreener
Will Precidian ETFs Trust AstraZeneca PLC stock maintain strong growth2025 Top Decliners & Comprehensive Market Scan Insights - BỘ NỘI VỤ
AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer - Citeline News & Insights
UK pharma giant AstraZeneca invest $2bn in Maryland manufacturing facility - BioProcess International
AstraZeneca gains US approval for Imfinzi in early gastric cancer treatment - Investing.com Nigeria
AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers - inkl
AstraZeneca PLCImfinzi approved in US for early gastric cancer - Research Tree
AstraZeneca (AZN) Gains U.S. Approval for Imfinzi in Cancer Trea - GuruFocus
FDA approves AstraZeneca’s IMFINZI for early-stage gastric cancer By Investing.com - Investing.com UK
AstraZeneca gains US approval for Imfinzi in early gastric cancer treatment By Investing.com - Investing.com South Africa
AstraZeneca’s Imfinzi Secures US Approval for Early Gastric Cancer Treatment - AskTraders.com
AstraZeneca Wins US Approval For Imfinzi In Early Gastric And GEJ Cancers - DirectorsTalk Interviews
FDA approves AstraZeneca’s Imfinzi for early-stage stomach and GEJ cancers - Investing.com UK
Astrazeneca's Imfinzi approved in US for early gastric cancer - MarketScreener
REGAstraZeneca PLCImfinzi approved in US for early gastric cancer - TradingView
FDA Clears AstraZeneca's Imfinzi as First Perioperative Immunotherapy for Gastric Cancers - MarketScreener
AstraZeneca's Imfinzi Regimen Gets US Approval for Treatment of Gastric, Gastroesophageal Junction Cancers - MarketScreener
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):